Search Results
Your search for it matches 15633 pages
Showing 51 - 100Dual Menin and KAT6A/7 Inhibition Improves Outcomes in NUP98-Rearranged Pediatric AML Models
A combination of menin inhibition and KAT6A/7 inhibition significantly improved survival for NUP98-rearranged pediatric acute myeloid leukemia (AML) in AML model systems, even in menin inhibitor–resistant cells, according to findings published in Cancer Discovery. The MYST gene family histone...
New Data Show Nearly 50% of All Cancer Deaths Worldwide Are Attributable to Modifiable Risk Factors
New reporting in The Cancer Atlas, Fourth Edition, showed that an estimated 50% of all cancer deaths worldwide are attributed to modifiable risk factors, including tobacco and alcohol use, infections, excess body weight, unhealthy diet, physical inactivity, ultraviolet radiation, environmental...
GPC3-Targeted ImmunoPET Helps Detect Earlier-Stage Hepatocellular Carcinoma
A novel immuno–positron-emission tomography (immunoPET) imaging agent targeting GPC3 demonstrated high sensitivity and specificity in detecting GPC3-positive hepatocellular carcinoma (HCC) tumors, including those under 1 cm, according to the results of a pilot clinical study presented at the...
Adding the Hepcidin Mimetic Rusfertide to the Standard of Care Yields Benefits in Polycythemia Vera
In patients with polycythemia vera requiring frequent phlebotomies, the investigational hepcidin mimetic rusfertide, given as a weekly subcutaneous injection, more than doubled the clinical response rate and significantly improved quality of life in the global phase III VERIFY study.1 These...
I Was Expecting to Hear I Have Heart Disease, Not Cancer
In 2022, I had a computed tomography (CT) coronary calcium scan to see whether there were any signs of narrowing or blockage in my heart arteries. Heart disease runs in my family. My father died of a heart attack the year before, and I worried that I was at risk for the same fate. It was a complete ...
W. Kimryn Rathmell, MD, PhD, FASCO, Selected for Women Who Conquer Cancer Mentorship Award
W. Kimryn Rathmell, MD, PhD, FASCO, has been selected for the prestigious 2025 Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. Launched in 2016, the Women Who Conquer Cancer award program honors extraordinary women leaders in oncology and role models who have excelled as mentors...
William C. Wood, MD, FASCO, Renowned Surgeon, Esteemed Mentor, Global Academic Dean, Dies at 84
William C. “Bill” Wood, MD, FASCO, a leader and mentor in the field of breast cancer, died on August 18, 2024. He was 84. Dr. Wood was the J.B. Whitehead Professor and Chair of the Department of Surgery at Emory University School of Medicine from 1991 to 2009. He chaired the 1990 U.S. National...
Malignant Hematology Expert and Medicare Reimbursement Advocate, Samuel M. Silver, MD, PhD, FRCP, FASCO, MACP, Dies at 74
The ASCO Post would like to pay tribute to Samuel M. Silver, MD,PhD, FRCP, FASCO, MACP, who died on August 14, 2024, at the age of 74. Dr. Silver was renowned in the hematology and oncology community and a respected member of the editorial advisory board of The ASCO Post. Additionally, he served...
Minnesota Society of Clinical Oncology Recognized for Advocacy at 2025 ASCO Annual Meeting
The Minnesota Society of Clinical Oncology (MSCO) is the recipient of the 2024 Jeffery C. Ward Affiliate Advocacy Award. The Association for Clinical Oncology presented the award during the State Affiliates’ Reception at the 2025 ASCO Annual Meeting. Presented annually, the Jeffery C. Ward...
Number of Cancer Survivors in the United States Reaches 18.6 Million and Projected to Exceed 22 Million by 2035
The number of people living with a history of cancer in the United States is estimated at 18.6 million as of January 1, 2025, and projected to exceed 22 million by 2035, according to a new report, Cancer Treatment and Survivorship Statistics, 2025, led by the American Cancer Society (ACS). The...
Chinese Herbal Medicine for Improving Adjuvant Chemotherapy Completion in Patients With Colon Cancer
Guest Editor’s Note: Although guidelines recommend adjuvant combination chemotherapy for patients with stage II and III colon cancer who are at high risk of disease recurrence, fewer than 50% complete treatment because of fear of adverse effects or symptom burden. The herbal formula Jianpi Bushen ...
Preoperative Endocrine Therapy for Older Women With Estrogen Receptor–Positive Breast Cancer: Impact on Radiotherapy Decisions
Providing a brief, 90-day course of preoperative endocrine therapy to older women with early-stage, estrogen receptor–positive, invasive breast cancer may significantly alter both patient preferences and physician recommendations regarding adjuvant radiation therapy, according to data presented...
HLA-Matching Considerations for Hematopoietic Cell Transplantation in Hematologic Malignancies
Besides relapse of the malignant disease, graft-vs-host disease is still one of the greatest concerns, in terms of adverse effects, following a hematopoietic cell transplantation (HCT) in a patient with a hematologic malignancy. To mitigate these concerns, investigators are continually analyzing ...
Vepdegestrant vs Fulvestrant in Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
Based on the findings of the VERITAC-2 trial, treatment with the selective PROTAC (proteolysis targeting chimera) estrogen receptor degrader vepdegestrant yielded statistically significant and clinically meaningful improvement in progression-free survival in patients with ESR1-mutant, estrogen...
National Comprehensive Cancer Network Launches NCCN Guidelines Navigator
The National Comprehensive Cancer Network® (NCCN®) has announced a new, interactive digital delivery format for the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The NCCN Guidelines® are the recognized standard for clinical decision-making and policy in cancer care and are the...
ASCO Guideline Update Calls for Omission of SLNB in Select Patients With Early-Stage Breast Cancer
ASCO has released a clinical practice guideline update on the role of sentinel lymph node biopsy (SLNB) in early-stage breast cancer.1 The update includes recommendations based on findings from trials released after the published guideline in 2017, including data from nine randomized trials...
In Second-Line Setting, T-DXd Improves Survival Outcomes in HER2-Positive Gastric or Gastroesophageal Junction Cancer
In the phase III DESTINY-Gastric04 trial, use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was compared head to head with the monoclonal antibody ramucirumab and paclitaxel in patients with previously treated, HER2-positive metastatic gastric or gastroesophageal junction...
Updated Results Confirm Benefit of Combination Regimen in BRAFV600E–Mutated Metastatic Colorectal Cancer
Patients with previously untreated BRAF V600E–mutated metastatic colorectal cancer who receive the BRAF inhibitor encorafenib and the EGFR inhibitor cetuximab plus mFOLFOX6 (modified leucovorin, fluorouracil, and oxaliplatin) vs the current standard of care (chemotherapy ± bevacizumab) may live...
FDA Approves Label Expansion for Agent Used in Patient Selection for Pre-Taxane Radioligand Therapy
The U.S. Food and Drug Administration (FDA) has approved a label expansion of a kit for the preparation of gallium Ga-68 gozetotide for injection (Illuccix) to include patient selection for radioligand therapy in the pre-taxane setting. The update applies to the imaging agent’s third indication,...
Silence Is Complicity
On January 20, 2025, newly sworn-in President Donald J. Trump signed Executive Order 14151, “Ending Radical and Wasteful Government DEI Programs and Preferencing,”1 effectively eliminating all diversity, equity, and inclusion (DEI) programs, preferences, and activities across the federal...
Adjuvant Use of Atezolizumab Plus Chemotherapy in DNA Mismatch Repair–Deficient Colon Cancer
For the adjuvant treatment of stage III colon cancer with DNA mismatch repair–deficient (dMMR) tumors, the addition of the checkpoint inhibitor atezolizumab to standard chemotherapy significantly improved disease-free survival in the phase III ATOMIC trial. The results position this approach as a...
Phase III Trial Results Suggest a New Standard of Care in Metastatic HER2-Positive Breast Cancer
In the phase III DESTINY-Breast09 trial, first-line treatment with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) plus the monoclonal antibody pertuzumab significantly delayed disease progression by more than 1 year—nearly doubling the time of disease control—over standard...
Cohort Study Finds Genetics of Cardiomyopathy Risk in Cancer Survivors Differ by Age of Onset
The relationship between genetic variants and the risk of late-onset cardiomyopathy remains poorly understood in survivors of childhood cancer despite being otherwise well established. Scientists from St. Jude Children’s Research Hospital have helped address this gap, assessing whether variant...
New Model Predicts Risk of Progression in Early-Stage Classical Hodgkin Lymphoma
The first individualized risk prediction model for adults with early-stage classical Hodgkin lymphoma (cHL) has been developed and validated. According to a report published in NEJM Evidence, the Early-Stage cHL International Prognostic Index (E-HIPI) model estimates 2-year progression-free...
Gut Microbiome May Hold Key to Avoiding Chemotherapy-Related Cardiotoxicity in Patients With Breast Cancer
A healthy gut microbiome prior to chemotherapy could help protect against cardiotoxicity as a result of breast cancer therapy, according to new findings presented by Antoniades et al at the European Society of Cardiology (ESC) Cardio-Oncology 2025 annual conference. Background Cardiotoxicity is a...
ASH 2025 Awardees: Hematologists to Be Honored With Highest Distinctions
The American Society of Hematology (ASH) announced that it will recognize 11 hematologists who have made notable contributions to the field with several honorific awards and prestigious lectures at the 2025 ASH Annual Meeting & Exposition in Orlando, Florida, from December 6–9, 2025. The...
How a Commonly Inherited Genetic Alteration Is Driving Breast Cancer Metastasis and Predicting Survival
A common germline variant in the proprotein convertase subtilisin/kexin type 9 (PCSK9) (rs562556, V474I) gene rather than a mutation in a breast cancer tumor may be the driving force in significantly increasing the risk of breast cancer metastasis and reducing survival in women with the disease....
Establishing Novel Models of Interdisciplinary Care to Improve Survival Outcomes in Patients With Cancer
Internationally renowned for her decades-long pioneering research in pancreatic cancer, in 2024, Diane M. Simeone, MD, left her positions as the Laura and Isaac Perlmutter Professor of Surgery and Pathology; Director, Pancreatic Cancer Center; and Associate Director of the Perlmutter Cancer Center...
How I Discuss the Current Political Chaos When Patients Ask Health-Related Questions About It
I’ve been a physician for several decades, seeing patients and functioning as a medical teacher; clinical, translational, and bench researcher; and administrator. Adapting to medical practice in three nations and several U.S. states has been quite challenging at different times, but I really think...
Outcomes of Oncologic Extended Resection for Gallbladder Cancer: Results of a Global Analysis
In the United States, approximately 55% of patients with resected gallbladder cancer undergo oncologic surgery without additional systemic treatment. However, as gallbladder cancer progresses to T3 (locally or regionally advanced) or T4 (distant metastasis) disease, the tumor frequently infiltrates ...
Novel Tri-Specific Antibody Shows Efficacy and Safety in Refractory Myeloma
According to the initial findings of an ongoing first-in-human phase I trial, reported at the European Hematology Association (EHA) 2025 Congress, promising results have been shown for a novel off-the-shelf tri-specific antibody in the treatment of patients with multiple myeloma highly refractory...
Experimental Approach to GVHD Prophylaxis Offers Alternative to Standard Regimen
Prevention of graft-vs-host disease (GVHD) was superior with a cyclophosphamide/cyclosporin-based regimen compared with standard prophylaxis in patients receiving a matched-sibling donor stem cell transplant in a large Australian randomized trial, investigators reported at the European Hematology...
Polatuzumab Vedotin–Based Regimen Improves Overall Survival in Refractory DLBCL
Combining the CD79b-directed antibody-drug conjugate polatuzumab vedotin-piiq with rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved survival outcomes in patients with transplant-ineligible, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), over standard rituximab ...
Chronicling the Extraordinary Career of Stephen R. Grobmyer, MD, FACS, in Breast Cancer Research, Surgery, and Treatment
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Stephen R. Grobmyer, MD, FACS, about his clinical and research career in oncology, the challenges and rewards of moving to Abu Dhabi and building a state-of-the-art cancer center, and...
BRCA Mutations Could Increase Risk of Rare Lymphoma Among Women Who Received Textured Breast Implants During Breast Cancer Treatment
The risk of developing breast implant–associated anaplastic large-cell lymphoma (ALCL) could be higher among women with breast cancer and BRCA1 or BRCA2 mutations who received textured breast implants as part of their postmastectomy reconstructive surgery compared with patients lacking the genetic...
Study Defines Divergent Molecular Pathways in HPV-Associated vs HPV-Independent Sinonasal Cancers
Findings from a comprehensive genome-wide study of sinonasal squamous cell carcinomas demonstrated that human papillomavirus (HPV) can drive tumorigenesis in some cases, and these tumors exhibit similar mutational patterns to those seen in HPV-associated cervical and head and neck squamous cell...
Colorectal Cancer Screening: CT Colonography vs Stool Testing
Computed tomography (CT) colonography demonstrated greater clinical efficacy and cost savings than stool DNA testing for colorectal cancer screening, according to results of a study published in Radiology. "Among the safe, minimally invasive colorectal cancer screening options, CT colonography is ...
Could A Telehealth Program Enhance Geriatric Cancer Care?
A telehealth-based care program may improve daily functioning, mood, disease understanding, and quality of life among older adults with cancer, according to a recent study published by Bergerot et al in JNCCN–Journal of the National Comprehensive Cancer Network. Study Methods and Results...
CancerCare Survey Reveals How Insurance Red Tape Impacts Cancer Treatment Delays
Findings from a first-of-its-kind national survey are included in “The Health Insurance Maze: How Cancer Patients Get Lost in the Red Tape of Utilization Management,” a new report from CancerCare which details the impact that prior authorization requirement and coverage stoppages have on patients...
Low-Value Cancer Screenings May Continue for Years Following Guideline Change to Limit Unnecessary Tests
Stopping the widespread use of unnecessary, potentially harmful cancer screenings may take up to 13 years and potentially longer following the implementation of new guidelines, according to a recent study published by LeLaurin et al in BMJ Quality & Safety. Background The U.S. Preventive...
Cutting Cancer Research Funding Is A Costly Gamble With Millions of Lives
“The [National Cancer Institute (NCI)] is a national treasure. If funding is diminished, it will be catastrophic to millions of patients and families who will experience the devastation of cancer in the coming years,” Richard J. Boxer, MD, wrote in an editorial Viewpoint published in JAMA Oncology ...
AACR Statement on Former President Joseph Biden’s Cancer Diagnosis
The American Association for Cancer Research (AACR) has issued the following statement regarding former President Joseph R. Biden’s prostate cancer diagnosis: “The American Association for Cancer Research (AACR) offers heartfelt support and well wishes to former President Biden and his family as...
I Was an N-of-1 in a CAR T-Cell Therapy Trial for Ovarian Cancer
More than a decade after I was diagnosed with late-stage ovarian cancer, a phase I clinical trial at Moffitt Cancer Center and Research Institute in Tampa, Florida, investigating a dose of a novel follicle-stimulating hormone receptor (FSHR)-targeting chimeric antigen receptor (CAR) T-cell therapy...
ESTRO 2025: Major Advances in Radiotherapy for Anal and Rectal Cancers
In May in Vienna, five studies presented at ESTRO (European Society for Radiotherapy and Oncology) 2025 showcased how radiotherapy is reshaping the landscape for anal and rectal cancers. From reduced-dose treatments to cutting-edge combinations with immunotherapy and chemotherapy, these innovations ...
Why Black Women Have a Higher Risk of Dying of All Types of Breast Cancer Than White Women
The disparities in breast cancer incidence and mortality rates between Black and White women in the United States have been well documented. Studies over the past decade consistently show that although Black women have a 4% lower breast cancer incidence rate than White women, they are still between ...
ASTRO Survey Data Illustrate Impact of Continued Medicare Cuts on Cancer Care
Recent national survey data from the American Society for Radiation Oncology (ASTRO) have shown that further cuts to Medicare reimbursement for radiation therapy would increase patient wait times for cancer treatment and force clinic downsizing. Nearly all (96%) of the 675 physicians responding to...
Expanded Treatment Options for Metastatic CRPC: ASCO Guideline Addresses Somatic Genetic Testing, Radiopharmaceuticals
The management of metastatic (CRPC) has rapidly accelerated in the past decade, giving oncologists a wider range of tools to work with and patients new opportunities for improving survival and maintaining quality of life. These significant advancements have prompted ASCO to release a guideline...
How the Elimination of Federal Gender-Related Grants and DEI Programs Is Impacting LGBTQ+ Health Research
Within hours of the start of his second administration, on January 20, 2025, President Donald Trump signed an executive order proclaiming that the country would now recognize only two sexes, male and female, essentially rejecting transgender identity, and directing all federal agencies to use the...
Improving the Alliance Between Oncologists and Primary Care Providers: A Call for Collaborative Action
Experts and patients alike would agree that navigating the current fragmented U.S. health-care system is not an easy task. One component of that disconnection may center on the relationship between oncology and primary care. The benefits of collaboration between oncologists and primary care...
Digital Histopathology and Automated Classification of Pediatric Sarcomas
With more than 50 different subtypes, pediatric soft-tissue sarcomas represent a broad category of disease. And given the rarity of these sarcomas, “it is difficult for pathologists to see a sufficient volume to gain expertise across all variants,” stated Adam Thiesen, BA, MD/PhD Candidate at UConn ...
